PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Detaylı Bibliyografya
Yazar: Lubaba, Anikah
Diğer Yazarlar: Fariha, Luluel Maknun
Materyal Türü: Tez
Dil:English
Baskı/Yayın Bilgisi: Brac University 2024
Konular:
Cardiovascular disease
CVD
Cholesterol-lowering therapy
Hyperlipidemia
Monoclonal antibody
PCSK9
Heart > Diseases > Treatment
Coronary heart disease > Treatment
Cholesterol > Pathophysiology
Online Erişim:http://hdl.handle.net/10361/23252

Internet

http://hdl.handle.net/10361/23252

Benzer Materyaller